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The origin of hyperthyroidism in Graves’ disease was displayed demonstrating 
the complexity of the processes. The role of stimulating TSH receptor antibodies 
is the one factor for the production of increased thyroidal T3 and T4. The T3 and 
T4 formation in colloid-embedded thyroglobulin and the activities of thyroidal 
deiodinases [type 1 (DIO1) and type 2 (DIO2)] play a crucial role in that. The 
findings of different authors were summarized with respect to highlighting the 
role of tissue-specific deiodinase activities. Apart from the results of experimental 
studies, the clinical results were brought to the front. The role of tissue-specific type 
2 deiodinase activity was demonstrated according to thyroid function, the presence 
of autoantibodies against thyroid peroxidase (TPO), thyroglobulin (Tg) and TSH 
receptor. Autoantibodies against human eye muscle membrane and cytosol antigens 
had influencing effects on tissue-specific DIO2 activities, and the antieye muscle 
antibody immunoglobulin isotypes were associated with eye muscle enlargements. 
Antithyroid drug (ATD) therapy demonstrated relevant effects on tissue-specific 
DIO2 activities, which were manifested in the alterations of thyroid hormone levels. 
An asymptomatically appearance of autoantibodies against peptides corresponding 
to amino acid sequence of DIO2 was detected associating with thyroid hormone and 
anti-TPO, anti-Tg and TSH receptor antibody levels during the therapy.
Keywords: hyperthyroidism, Graves’ disease, type 1 and type 2 deiodinases, 
ophthalmopathy, autoantibodies
1. Introduction
Graves’ hyperthyroidism is characterized by increased thyroid hormone levels 
(T4 and T3) with the supprimation of TSH levels, diffuse enlargement of thyroid 
glands and associated symptoms with orbitopathy or/and dermopathy [1, 2]. The 
course of disease is characterized by duality. The main autoimmune processes are 
manifested in thyrotoxicosis with a lymphocytic infiltration and diffuse thyroid 
enlargement, which can be associated with orbitopathy in 15–25% and pretibial 
myxedema in 0.5–4.5% [3]. The autoimmune processes are associated with the 
development of autoantibodies against different antigens, such as thyroid antigens 
[TSH receptor, thyroid peroxidase (TPO) enzyme and thyroglobulin (Tg)] and 
IGF-1 receptor, as well as against extraocular muscle membrane and cytosol anti-
gens, and intracellular particles (flavoprotein subunit of mitochondrial succinate 
dehydrogenase, sarcalumenin, calsequestrin, collagen XII)] in thyroid-associated 
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ophthalmopathy [4–7]. The increased production of proinflammatory cytokines 
(IL-1, IL-6, TNFα), chemokines and costimulatory ligands on fibroblasts and 
adipocytes lead to inflammatory and infiltrating processes, and glycosaminoglycan 
(GAG) accumulation resulting in local tissue enlargements [8, 9]. In orbitopathy, 
the local infiltrating processes are responsible for the proptosis and sometimes the 
damage of nervi optici that can reach vision loss in the final stage. TSH receptor 
stimulating antibodies are kept to be the causative factors for hyperthyroidism. 
Autoantibodies against IGF-1 nearby receptor are involved in the edematous-infil-
trative processes [10]. Antibodies against thyroid peroxidase (TPO) and thyro-
globulin (Tg) are the relevant thyroid autoantibodies in Graves’ disease [11]. The 
binding of IgG and IgA autoantibodies to human extraocular muscle was different: 
IgG types bound endomysially, while IgA types bound to muscle fibers [12].
Deiodinase enzymes, DIO1, DIO2 and DIO3 are responsible for the conversion 
of T4 to active T3 hormone, the maintenance of the local T3 levels and the inactiva-
tion of T4 and T3 hormones [13, 14]. Deiodinase enzymes show tissue-specific 
expression, which limits their functions. Many drugs, iodine and selenium supply, 
proinflammatory cytokines and autoantibodies can influence DIO activities [15, 16]. 
The increased T4 levels are connected to the acceleration of the physiological deg-
radation of DIO2 enzyme [17]. The common localization of DIO2 enzyme between 
thyroid and eye muscle tissues suggests that its autoantigenic role can be important 
in Graves’ ophthalmopathy [18, 19]. 5′-deiodinase enzymes (DIO1 and DIO2) play a 
crucial role in thyroid hormone synthesis. TPO enzyme plays a role in the iodination 
of tyrosyl residues and their coupling to T3 and T4 in the colloid-embedded Tg with 
the interaction of hydrogen peroxide (H2O2) at the apical plasma membrane of 
thyrocytes [20]. The schematically illustrated process of thyroid hormone synthesis 
is exhibited in Figure 1 highlighting the role of DIO1 and DIO2 activities.
Figure 1. 
Schematic illustration of thyroid hormone synthesis and thyroidal deiodinase activities (DIO1 and DIO2). 
DIO1: Type 1 deiodinase; DIO2: Type 2 deiodinase; Tg: Thyroglobulin; TPO: Thyroid peroxidase; T2, T3 and 
T4: Iodothyronines with 2, 3 and 4 iodides.
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This review emphasizes the role of deiodinases in the hyperthyroidism of 
Graves’ disease with respect to the thyroid functional stages and the relationship 
with antithyroid autoantibodies and autoantibodies against extraocular muscle and 
peptides corresponding to amino acid sequence of DIO2, as well as with the antithy-
roid drug (ATD) therapies.
2.  Three types of deiodinase enzymes are involved in thyroid hormone 
activation and inactivation
Three types of deiodinase enzymes (DIO1, DIO2, DIO3) are responsible for the 
activation and inactivation of thyroxine (T4) and triiodothyronine (T3) thyroid 
hormones [21]. Deiodinase enzymes demonstrate tissue-specific localization. DIO1 
enzyme is expressed in the liver, kidney and thyroid parenchymal cells localized 
in the plasma membrane [22]. Its active center is found in the cytosol. T4 plays as a 
prohormone for the active T3 hormone. T4 has four iodine bindings at the 3,3′, 5 and 
5′ positions. DIO1 enzyme is able to cleave iodine from 5 (inner ring deiodination, 
step of T4 inactivation) or 5′ position (outer ring deiodination, step of active T3 
hormone production). The dual effect of DIO1 enzyme plays a crucial role in the 
excessive thyroid hormone production, called hyperthyroidism. DIO2 enzyme is a 
widespread 5′-deiodinase expressed in thyroid, skeletal muscle and adipose tissues, 
hypothalamus, pituitary, skin, osteoblast, astroglia, retina, cochlea, placenta and 
endothelial cells localized in the endoplasmic reticulum [23]. Its active center is 
found in the cytosol. DIO1 expression can be induced transcriptionally by T3 and 
TSH receptor stimulating antibodies. Fasting and chronic illnesses decrease DIO1 
activity. The inhibitory effect on thyroidal DIO1 and DIO2 activities was demon-
strated in vitro in the presence of proinflammatory cytokines (IL-1, IL-6 and TNFα) 
[24]. The inhibitory rate was higher on DIO2 than on DIO1 activities. The inhibitory 
degree was dose-dependent. Thyroidal DIO1 activity is responsible for only 6% 
of the daily T3 production [25]. Propylthiouracil (PTU) inhibits its activity. DIO2 
plays a crucial role in the maintenance of intracellular T3 levels via 5′-deiodination, 
converting T4 to T3. Its increased activity is partly present in hyperthyroidism; 
however, its activity is decreased in nonthyroidal illness [26]. DIO2 is a posttransla-
tionally T4-dependent enzyme, which accelerates its proteasomal degradation. DIO2 
enzyme is involved in the feedback mechanism of hypothalamic–pituitary-thyroid 
axis [27]. The normal development and regeneration of skeletal muscle requires 
DIO2 activity [28].
DIO3 is an enzyme located in the plasma membrane. It has both extra- and 
intracellular activity [29]. DIO3 plays a crucial role in fetal development and 
tissue-repair. It is expressed in placenta, uterus, neurons, skin, alveolar cells, glial 
cells, urothelium, gastrointestinal tract, hypothalamus and skeletal muscle [30]. 
DIO3 inactivates T3 through inner ring 5-deiodination. Its increased activity is 
responsible for the consumptive hypothyroidism observated in hepatic heman-
giomas [31]. Nether DIO2 nor DIO3 are PTU sensitive enzymes. Hypothyroidism 
is connected to an increase in DIO1 and DIO2 activities, but DIO3 activities are 
decreased [22]. Hyperthyroidism is connected to an increase in both thyroidal 
DIO1 and DIO2, but to a decrease in extrathyroidal DIO2 activities. Iopodic 
acid, the contrast material with high iodine content decreases the activities of 
all deiodinase enzymes. The alterations in T4 and T3 levels according to thyroid 
function have a different effect on the deiodinase enzyme activities in the living 
cells vs. sonicated cells [23]. No protein synthesis can happen in sonicated cells. 




3.  The role of DIO1 and DIO2 deiodinase enzymes in thyroid hormone 
production of Graves’ hyperthyroidims
Hyperthyroidism is characterized by increased serum FT4 and FT3 levels, which 
can be associated with Graves’ disease, toxic goiter, destruction-induced thyrotoxi-
cosis and subacute thyroiditis. Thyroid follicular cells possess both DIO1 and DIO2 
enzymes, but not DIO3 enzyme. The amount of produced FT4 and FT3, and the 
ratio of FT3 to FT4 can help with the diagnosis [32]. Serum FT3 levels are predomi-
nant and are better formed than FT4 in hyperthyroidism connected to Graves’ 
disease or toxic goiter [33]. In Graves’ hyperthyroidism, the increase in the daily 
production of T3 and T4 was 7-fold and 3.5-fold, respectively. Laurberg and cowork-
ers demonstrated that the major source of excess T3 derived from increased thyroi-
dal DIO1 and DIO2 activities (in a ratio of 3 to 1). This is in contrast to what is found 
in euthyroidism, where 20% of T3 came from thyroidal production and 80% from 
extrathyroidal deiodination [25]. In hyperthyroidism, a large part of T3 levels was 
produced by the thyroid (in 57–77%) by way of converting T4 to T3 with decreased 
peripheral deiodination. The extrathyroidal DIO2 activities were decreased in 
hyperthyroidism with the exception of the thyroidal one due to the increased 
thyroidal formation of T4 and T3. Maia and coworkers supported that thyroidal 
DIO1 activity is responsible for 67% of T3 production in hyperthyroidism [22]. In 
HEK 293 cells, which transiently expressed DIO1 and DIO2 enzymes, the effect of 
2–20-200 pM T4 was studied on these cells modeling hypo-, eu- and hyperthyroid 
states. DIO1 activity was continuous, but DIO2 activity was decreased by the 
concentration of 200 pM T4. Salvatore and coworkers emphasized the greater role 
of DIO2 enzyme in the excess T3 in Graves’ hyperthyroidism [34]. Ito and coworkers 
suggested that thyroidal DIO1 and specifically, DIO2 could be contributed to the 
higher ratio of FT3 to FT4 in Graves’ hyperthyroidism [35]. The lower ratio of T3 to 
T4 can help us with the diagnosis of destruction-induced thyrotoxicosis and sub-
acute thyroiditis [36]. Values less than of 20 confirm the above mentioned diseases, 
while the values above 20 are connected to Graves’ hyperthyroidism. Weetman and 
coworkers made the DIO1 and DIO2 activities responsible for the syndrome of low 
T4 with increased T3 levels during PTU treatment [37]. Thyroidal DIO1 activity 
is mainly regulated by cAMP at pretranslational levels, similarly to TSH receptor 
stimulating antibody-induced cAMP. Thyroglobulin and iodine contents of thyroid 
can influence the generation of T4 and T3 through the rate of hydrolysis from the 
colloid-embedded thyroglobulin. This condition can contribute to the alterations 
in the production of thyroid hormones. Very few reports could be found, which 
explained in detail the thyroid hormone production connecting to the formation of 
the coupling mechanism alone or together with deiodinase conversion. Iodide alone 
inhibited both thyroidal deiodinase activities rapidly decreasing the circulating T3 
by 50% and T4 by 70% [33]. Ipodate is also a potent inhibitor for DIO1 and DIO2 
enzymes due to its iodine content of 64%. Ipodate with PTU resulted in a profound 
decrease in serum T3. In untreated Graves’ hyperthyroidism, the T3 content of Tg 
was 2-fold of what was found in euthyroidism [38]. In hyperthyroidism, local DIO2 
activity is required for the intrapituitary production of T3, which is responsible for 
the acute decrease in TSH levels [39].
4. In vitro model for the measurement of tissue-specific DIO2 activities
In our study, homogenized (supernatant of 100 000 x g separated by centrifuga-
tions) thyroidal, skeletal and eye muscle tissue fractions, called cytosol fractions 
were applied for the measurements of deiodinase enzyme activities [40]. Thyroid 
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tissues were obtained from the removal of euthyroid goiter; the removal of skeletal 
muscle during accident surgery and the removal of extraocular muscle during 
strabismus surgery. All tissue fractions contained DIO2 enzyme, the activity of 
which was measured in the presence of patient sera with Graves’ disease with 
respect to the different thyroid hormonal stages. The DIO2 content of cytosol 
fractions was proofed before the study using guinea pig sera immunized with TCSS 
and LVFR peptides. Both peptides were corresponding to amino acid sequences of 
human DIO2 (GenBank AAD45494–1) and contained the selenocysteine at position 
133 in the active center of the enzyme: LVVNFGSATCPPFTSQLPAFRKLVEEFSS. 
TCSS peptide (aa 132–152): TCCPPTFSQLPAFRKLVEEFSS was synthesized with 
double cysteins replaced at position 133, as well as amino acids reserved at posi-
tions 136 and 137. LVFR peptide (aa 124–144): LVVNFGSATCPPFTSQLPAFR was 
100% identical to the original amino acid sequence. The bindings of immunized 
sera to cytosol fractions and to tissue sections were investigated with enzyme-
linked immunosorbent assay (ELISA) and immunohistochemistry, respectively. 
Immunized sera against TCSS peptide resulted in more intensive positive bindings 
to the cytosol fractions and gave positive reactions to tissue sections.
The patient sera of hyper-, eu- and hypothyroid Graves’ disease were added 
to thyroidal, skeletal and eye muscle cytosol fractions, which contained DIO2 
enzyme activities. The study could be considered as an in vitro model, in which 
the patient sera included the actual hormonal and autoantibody parameters. The 
effects of these parameters were measured on DIO2 activities. The results, after 
evaluating them with respect to the parameters, may contribute to gaining use-
ful data for the course and treatment of disease. Thyroidal DIO1 activities were 
inhibited by 2 μM PTU. The sample mixture contained 12.5 μg protein per cytosol 
fraction. Radioiodine labeled T4 (
125I-T4) 1 kB/50 μl was the substrate in reducing 
condition [20 mM dithiothreitol (DDT)]. The results were extrapolated at 1 pmol/
T4 of patient serum. DIO2 enzyme activity was expressed as pmol of T4 converted 
per mg/min of protein. The whole protocol is described in detail in our previous 
paper [41].
5.  Recent research with tissue-specific DIO2 activities in Graves’ 
hyperthyroidims
5.1  Measurement and evaluation of DIO2 enzyme activities: DIO2 enzyme 
activities were measured after adding patient sera with Graves’ 
ophthalmopathy to thyroidal, skeletal and eye muscle cytosol fractions, 
all containing DIO2 enzymes. The results were then evaluated according to 
thyroid functional stages
Fifty-two patients with Graves’ disease, of whom 37 had ophthalmopathy, were 
investigated [42]. The difference in the disease duration, the ratio of FT3 to FT4 and 
the serum levels of TSH receptor antibodies was significant between the Graves’ 
patients with and without ophthalmopathy. The difference in DIO2 activities was 
relevant and constant among thyroidal, skeletal and eye muscle cytosol fractions in 
hyper-, eu- and hypothyroidism in Graves’ ophthalmopathy. The effect of increased 
serum FT4 levels was 1.9 times greater on eye muscle DIO2 than thyroidal DIO2 
activity. The findings demonstrated that, the tissue-specific DIO2 activities also 
play a crucial role in the T3 content of peripheral tissues in hyperthyroidism. The 
skeletal muscle and thyroidal DIO2 activities were lower by 27% and 47%, respec-
tively in hyperthyroidism, as well as were lower by 27% and 87%, respectively 
in hypothyroidism compared to eye muscle DIO2 activity. DIO2 activities of all 
Graves’ Disease
6
cytosol fractions were 6.3 times lower in hyperthyroidism and 3.5 times greater in 
hypothyroidism compared to those in euthyroidism (Figure 2). In hyperthyroid-
ism, the thyroidal DIO2 activity was better inhibited than that of peripheral tissues. 
In hypothyroidism, increased thyroidal DIO2 activity could be found together with 
increased peripheral tissue DIO2 activities.
The effects of FT3 hyperthyroidism were identical on DIO2 activities in all 
cytosol fractions, but their activities were 2 times higher in euthyroidism com-
pared to those found by increased FT4 levels. No increase in any DIO2 activities 
could be detected with respect to FT3 levels in hypothyroidism compared to those 
in euthyroidism. The decrease in all DIO2 activities was the consequence of the 
increased FT4 levels, which demonstrated a substrate-mediated inhibitory effect 
in hyperthyroidism. Note, however, that the inhibitory effect of proinflammatory 
cytokines (IL-6, IL-1 and TNFα) and the therapy cannot be excluded in some cases. 
Our previous study confirmed the role of IL-6 in Graves’ ophthalmopathy with 
active eye signs [43]. The presence of inflammatory orbital events and a longer 
manifestation of ophthalmopathy were associated with increased serum IL-6 levels. 
Therefore, the autoimmune features of Graves’ disease can modify DIO2 activities. 
The increased DIO2 activities in all cytosol fractions in FT4 hypothyroidism could 
be explained by the concomitantly increased serum levels of TSH receptor antibod-
ies compared to those in FT3 hypothyroidism. Nevertheless, serum TSH levels were 
not suppressed by increased serum FT4 levels, which could be explained by the pitu-
itary resistance to T4 [44]. No similar results could be demonstrated for increased T3 
levels. Contrary to FT4 hypothyroidism, the lack of increased DIO2 activities in FT3 
hypothyroidism support that in this condition the active protein synthesis of DIO2 
enzyme is needed for increasing their activities. The partly increased skeletal and 
eye muscle DIO2 activities in both FT4 and FT3 hyperthyroidism excluded a relevant 
inactivating role of DIO3 in muscle cytosol fractions.
DIO2 activities in all cytosol fractions were significantly lower in Graves’ 
ophthalmopathy with increased serum FT3 levels keeping the proportional dis-
crepancies constantly among thyroidal, skeletal and eye muscle DIO2 activities. 
However, Graves’ sera without ophthalmopathy resulted in a 5-fold increase in all 
Figure 2. 
The effect of patient sera with Graves’ disease on thyroidal, skeletal and eye muscle DIO2 activities with respect 
to thyroid functional stages based on FT4 levels. DIO2: Type 2 deiodinase.
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DIO2 activities still keeping the proportional discrepancies constant among thyroi-
dal, skeletal and eye muscle DIO2 activities. The elevation in TSH receptor antibody 
levels did not associated with DIO2 elevation, but it did with TSH suppression 
and with a lower ratio of FT3 to FT4. Note that due to the small number of patients 
without ophthalmopathy, the conclusions can be limited.
5.2  Effects of antithyroid and antiextraocular muscle autoantibodies on 
thyroidal, skeletal and eye muscle DIO2 activities
5.2.1  Thyroidal, skeletal and eye muscle DIO2 activities with respect to anti-TPO 
and TSH receptor autoantibodies in FT3 hyperthyroid Graves’ disease
The effects of autoantibodies against thyroid peroxidase (TPO) and TSH recep-
tor were investigated on thyroidal, skeletal and eye muscle DIO2 activities in FT3 
hyperthyroid Graves’ disease. A greater number of patients with ophthalmopathy 
(n = 11) demonstrated anti-TPO antibodies than those without (n = 4) [42]. Anti-
TPO antibody positive patients without ophthalmopathy exhibited 5 times greater 
DIO2 activities in thyroidal and skeletal muscle cytosol fractions, and even 12 times 
greater in eye muscle cytosol fraction compared to those with ophthalmopathy 
(Figure 3). DIO2 activities were compared between anti-TPO antibody positive and 
negative patients. The difference in all DIO2 activities were significant between the 
patients with and without ophthalmopathy in FT3 hyperthyroid Graves’ disease, as 
well as between anti-TPO antibody negative and positive patients. DIO2 activities 
increased 17 times in patients without ophthalmopathy, but decreased by 39% in 
patients with ophthalmopathy in the presence of anti-TPO antibodies compared 
to those who were negative for these autoantibodies (Figure 4). The alterations 
could be explained by the greater increased serum FT4 levels in anti-TPO antibody 
positive patients with Graves’ ophthalmopathy in contrast to the patients without 
ophthalmopathy. The patients without ophthalmopathy showed reduced FT4 levels, 
which were below the normal range, concomitantly with the elevated serum TSH 
levels. These result are limited by the small patient number of Graves’ disease 
without ophthalmopathy.
In FT3 hyperthyroidism, TSH receptor antibody positivity was greater in Graves’ 
ophthalmopathy (n = 11, and 9 out of 11 cases were anti-TPO antibody positive) 
Figure 3. 
The effect of patient sera with Graves’ disease on thyroidal, skeletal and eye muscle DIO2 activities in 
anti-TPO antibody positive patients between with (GO) and without (G) ophthalmopathy. DIO2: Type 2 
deiodinase; TPO: Thyroid peroxidase.
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than in those who had no ophthalmopathy (n = 2) [42]. DIO2 activities were signifi-
cantly increased in all cytosol fractions (increased by 3.6 times) for TSH receptor 
antibody positive patients compared to TSH receptor antibody negative patients 
with Graves’ ophthalmopathy, but the opposite was true for patients without 
ophthalmopathy (Figure 5). Surprisingly, in the absence of ophthalmopathy, TSH 
receptor antibody positive patients demonstrated relevantly decreased DIO2 activi-
ties, which were 10 times lower than those found in TSH receptor antibody negative 
patients in all cytosol fractions, concomitantly with the increased serum TSH levels.
5.2.2  The effects of IgG and IgM isotype antieye muscle cytosol and membrane 
autoantibodies on eye muscle DIO2 activity in Graves’ ophthalmopathy
Next, the effects of antieye muscle cytosol and membrane autoantibodies on eye 
muscle DIO2 activity were examined in Graves’ ophthalmopathy. Before the study, 
the binding reactivity of sera to human eye muscle membrane and cytosol antigens 
in tissue sections was controlled. In our previous results using immunohistochemis-
try and immunoblotting methods, antibodies against TCSS peptide, corresponding 
to amino acid sequence of DIO2 and eye muscle cytosol or membrane antigens 
(supernatant or pellet fractions of 100 000 x g, separated by centrifugations) were 
demonstrated, which gave intensive binding reactions to human thyroid, skeletal 
and eye muscle tissue sections [40].
The binding of guinea pig sera immunized by TCSS peptide could be inhibited 
by patient sera added in advance, which sera gave positive reactions to eye muscle 
tissue sections. Toyoda and coworkers investigated the DIO1 enzyme activity in 
FRTL-5 rat thyroid cells in the presence of IgG type immunoglobulins derived from 
untreated hyperthyroid Graves’ patients and controls [45]. They demonstrated a 
relevant increased DIO1 activity, which could be completely abolished by the addi-
tion of cycloheximide.
Based on the previously mentioned results we wanted to measure the effects of 
antieye muscle cytosol and membrane autoantibodies on eye muscle DIO2 activity, 
as well as to compare DIO2 activity to eye muscle enlargements. The hypothesis 
was, that antieye muscle autoantibodies may affect DIO2 activity, which can lead 
to eye muscle enlargement. We investigated the role of antieye muscle antibodies 
in Graves’ disease [46]. In turn, the appearance of these autoantibodies was not 
Figure 4. 
The effect of patient sera with Graves’ disease on thyroidal, skeletal and eye muscle DIO2 activities between 
anti-TPO antibody negative and positive patients with (GO) and without (G) ophthalmopathy. DIO2: Type 2 
deiodinase; TPO: Thyroid peroxidase.
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only connected to ophthalmopathy, but they could also be found in a small part 
of patients without ophthalmopathy. IgG, IgA and IgM isotype antieye muscle 
membrane and cytosol autoantibodies were measured with enzyme-linked immu-
nosorbent assay (ELISA) in 32 patients with hyperthyroid Graves’ disease, of 
whom 20 cases had ophthalmopathy. None of IgA isotype autoantibodies could be 
detected against membrane and cytosol antigens in any of the patients. A greater 
number of patients with ophthalmopathy demonstrated IgM (n = 10) and IgG 
(n = 5) antieye muscle autoantibodies than those without ophthalmopathy, of 
whom 3 cases had IgG type and 3 cases had IgM type autoantibodies. Surprisingly, 
the addition of serum containing IgG isotype antieye membrane (EyeM) or 
cytosol (EyeC) autoantibodies resulted in 6.4 times or 3.9 times increased eye 
muscle DIO2 activity, respectively compared to those found with IgG negative 
sera (Figure 6). Conversely, the effect of IgM type antieye muscle membrane or 
cytosol autoantibodies was associated with 3 times or 1.9 times lower eye muscle 
DIO2 activity, respectively. The presence of IgG type anti-EyeC autoantibodies 
resulted in 1.5 times greater eye muscle DIO2 activity than anti-EyeM autoantibod-
ies. A similar increase in DIO2 activity could be demonstrated in the presence of 
IgM type anti-EyeC autoantibodies compared to those with anti-EyeM autoan-
tibodies. In this instance, the increase in eye muscle DIO2 activitiy was 2 times 
greater. Furthermore, the increase in eye muscle DIO2 activity was 7 times and 5 
times higher in the presence of IgG type anti-EyeM and anti-EyeC autoantibodies 
compared to those in the presence of IgM type anti-EyeM and anti-EyeC autoanti-
bodies, respectively. Eye muscle DIO2 activities strongly correlated with IgG type 
anti-EyeM and anti-EyeC autoantibody levels. It seems, the autoantibody binding 
to eye membrane could mediate a signal towards the cytosolic DIO2 enzyme. The 
findings between eye muscle DIO2 activity and eye muscle enlargement suggest 
this idea. IgG type anti-EyeM autoantibodies were associated with increased eye 
muscle enlargement, although the difference was not significant. However, IgM 
type anti EyeM autoantibodies were associated with a significant decrease in eye 
muscle enlargement. The fact that IgM type anti-EyeM autoantibodies could play 
a role in DIO3 activity, could not be excluded. The eye muscle DIO2 activity was 
more greater in patients with the absence of ophthalmopathy compared to those 
in the presence of that. Our results suggest that autoantibodies against eye muscle 
Figure 5. 
The effect of patient sera with Graves’ disease on thyroidal, skeletal and eye muscle DIO2 activities between 




antigens have a role in the development of ophthalmopathy through the eye muscle 
enlargements. The limitation of this study was the small patient number containing 
IgM isotype anti-EyeM and IgG isotype anti-EyeC antibodies. Another limitation 
could be the measurement method of the eye muscle enlargements, which was done 
using ultrasound in the absence of CT or MRI possibilities.
5.3  The effect of antithyroid drugs on tissue-specific DIO2 activities, as well as 
their role in the induction of autoantibodies against DIO2 peptides
5.3.1  The effect of antithyroid drugs on thyroidal, skeletal and eye muscle DIO2 
activities
Antithyroid drugs (ATD) are used very often in the therapy of Graves’ hyper-
thyroidism. Methimazole (MMI) and propylthiouracil (PTU) are the medicines 
used to block the synthesis of thyroid hormones in Hungary. ATDs are thioamide 
derivates with the binding reaction to DIO1 enzyme forming an intermediary 
selenyl-iodide-DIO1 enzyme complex (presumably the same is true for DIO2 also). 
In addition, they inhibit the activity of TPO enzyme due to the impairment of H2O2 
generation and the coupling of iodotyrosines. MMI may be a selective DIO1 blocker 
and inhibits thyroidal H2O2 generation. However, MMI has no remarkable effect on 
DIO2 activity. PTU is a very strong inhibitor for DIO1 activity. None of the patients 
were treated with PTU in the tissue-specific DIO2 activity study.
The difference in thyroidal DIO2 activities was significant between those with 
and without ophthalmopathy in FT3 hyperthyroidism who did not undergo MMI 
therapy [42]. MMI therapy was associated with a greater increase in thyroidal, 
skeletal and eye muscle DIO2 activities in both patients without and with ophthal-
mopathy (the increase was 17 times and 4 times higher, respectively) compared to 
the increases in patients who were not treated with MMI. MMI therapy was associ-
ated with greater TSH levels and greater ratio of FT3 to FT4 in patients without 
ophthalmopathy, and greater TSH receptor antibody levels in patients with ophthal-
mopathy (Figure 7).
Figure 6. 
The effect of patient sera containing IgG and IgM type antieye muscle membrane (EyeM) and cytosol (EyeC) 
autoantibodies on eye muscle DIO2 activity in Graves’ ophthalmopathy. DIO2: Type 2 deiodinase.
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5.3.2  Occurrence of antibodies against peptides corresponding to amino acid 
sequence of DIO2 during antithyroid drug therapy and the efficacy of therapy
In another study, the occurrence of autoantibodies against DIO2 peptides, such 
as TCSS (cyspeptide) and LVFR (hompeptide) peptides were investigated in 78 
patients with hyperthyroid Graves’ disease [47]. The relationships were exami-
nated among ATD therapies, antibodies against TPO, thyroglobulin (Tg) and TSH 
receptor, as well as thyroid hormone levels. The appearance of autoantibodies 
against cys-, hompeptide or both peptides could be detected in 24, 4 or 9 cases, 
respectively, in Graves’ disease. The appearance of these autoantibodies was not 
associated with the clinical signs of urticaria or ANCA-associated vasculitis. These 
anticys- and antihompeptide antibodies could be demonstrated in 12 and 3 cases 
in hyperthyroidism, and in 10 and 1 cases in euthyroidism. A significant difference 
was found in the occurrence of anticyspeptide antibodies between PTU (n = 3 out 
of 3 cases) and MMI (n = 13 out of 42 cases) therapies. The frequency of antipep-
tide antibodies was smaller in Graves’ ophthalmopathy (9 cases for anticyspeptide 
antibodies and 1 for antihompeptide antibodies). The exact mechanism is not clear, 
but ATDs are thioamide drugs with the binding feature to DIO and TPO enzymes 
blocking the T4 conversion to T3, and the iodination with the phenolic coupling of 
iodothyrosine residues. Their higher binding features are connected to their greater 
reactivity with free radicals. Not only the asymptomatic occurrence of autoantibod-
ies against cys- and/or hompeptide was surprising in hyperthyroid Graves’ disease, 
but also their strong relationship with decreasing anti-TPO and increasing TSH 
receptor antibody levels (Figure 8). In hyperthyroidism, two antipeptide antibod-
ies possessed distinct features with relation to the occurrence of anti-TPO, anti-Tg 
and TSH receptor antibody levels, as well as to the thyroid hormone levels and the 
ratio of FT3 to FT4. Antibodies against cyspeptide were rather stimulating: Positive 
correlation could be demonstrated between anticyspeptide antibodies and serum 
FT4 levels; the ratio of FT3 to FT4 was increased when those antibodies were present 
compared to when they were absent. In Graves’ ophthalmopathy, the serum FT4 and 
FT3 levels were lower in the presence of antibodies against cyspeptide compared to 
when those antibodies were absent. The ratio of FT3 to FT4 was increased in patients 
Figure 7. 
The effect of patient sera who were treated with methimazole (MMI) on thyroidal, skeletal and eye muscle 
DIO2 activities in hyperthyroid Graves’ disease with and without ophthalmopathy. DIO2: Type 2 deiodinase.
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without ophthalmopathy compared to those when it was present (Figure 9). 
Antibodies against hompeptide and both peptides were rather inhibiting: anti-TPO 
and anti-Htg antibodies levels were reduced in their presences compared to when 
they were absent. In hyperthyroid Graves’ ophthalmopathy, antibodies against both 
peptides were associated with reduced antibody levels against TPO and Tg, but with 
increased TSH receptor antibody levels, particularly when the clinical activity score 
(CAS) was above 4. In FT4 hyperthyroidism, MMI treated Graves’ patients without 
ophthalmopathy, demonstrated significantly increased FT3 to FT4 ratio with the 
occurrence of anticyspeptide autoantibodies.
Figure 8. 
The effect of patient sera containing autoantibodies against peptides (hom – and/or cyspeptide) corresponding 
to amino acid sequence of DIO2 on the levels of anti-TPO and anti-Tg autoantibodies, as well as on the 
ratio of FT3 to FT4 in hyperthyroid Graves’ disease. DIO2: Type 2 deiodinase; TPO: Thyroid peroxidase; Tg: 
Thyroglobulin.
Figure 9. 
The effect of patient sera containing autoantibodies against cyspeptide corresponding to amino acid 
sequence of DIO2 on serum FT4 and FT3 levels, as well as on the ratio of FT3 to FT4 in hyperthyroid Graves’ 
ophthalmopathy and between the presence and absence of ophthalmopathy. DIO2: Type 2 deiodinase.
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The results in thyroid hormone levels supported that the presence of antipep-
tide antibodies before the treatment and their absence during the treatment with 
MMI may contribute to the worsening of orbital processes in hyperthyroid Graves’ 
ophthalmopathy. Antibodies against DIO2 peptides may influence the therapeutic 
efficacy during the treatment (Figure 10). In MMI treatment, the presence of anti-
bodies against hompeptide only was connected to increased serum FT4 levels, but 
when autoantibodies against both hom- and cyspeptide were present, it resulted in 
a relevant decrease in TSH receptor antibody levels. MMI treatment demonstrated 
lower TSH receptor antibody levels and lower ratio of FT3 to FT4 in the appearance 
of anticyspeptide autoantibodies compared to those treated with PTU. The exact 
role of antipeptide antibodies and their relationship with antithyroid autoantibod-
ies, as well as the possibility of the occurrence of autoantibodies against other 
amino acid sequence of the whole DIO2 protein need futher investigations.
6. Conclusions
In hyperthyroid Graves’ disease the thyroid hormone excess is dominantly 
T3. The thyroidal production of T3 and T4 excess can derive from the thyroidal T4 
and T3 formation in the colloid-embedded Tg mediated by thyroidal TPO, and 
the additional production of T3 due to deiodinase enzymes mediated conversion 
from T4 resulting in the ratio of 3 to 1 for DIO1 and DIO2 activities in the cytosol, 
respectively. The results using in vitro model for the study of tissue-specific DIO2 
activities confirmed the dominance of thyroidal DIO1 activity, but the thyroidal 
DIO2 activity seemed to be more reduced compared to skeletal and eye muscle 
DIO2 activities. The degree of DIO2 activities was tissue-specific, but the extent of 
their decreases in hyperthyroidism and increases in hypothyroidism was identical. 
The findings highlighted that the increase in tissue-specific DIO2 activity needed 
an active protein synthesis only in FT3, but not in FT4 hypothyroidism. The appear-
ance of anti-TPO, TSH receptor, and antieye muscle membrane and cytosol auto-
antibodies modified the tissue-specific DIO2 activities, which manifested in both 
Figure 10. 
The effect of patient sera containing autoantibodies against peptides (hom- and/or cyspeptide) corresponding 
to DIO2 amino acid sequence on serum FT4 and TSH receptor antibody levels, as well as on the ratio of FT3 
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increased and decreased serum TSH levels and sometimes in eye muscle enlarge-
ments. Besides the effect of ATDs on tissue-specific DIO2 activities, autoantibodies 
against peptides corresponding to amino acid sequences of DIO2 also appeared 
asymptomatically in Graves’ disease. Furthermore, they were also detectable before 
ATD therapy, and the therapy increased their occurrences. The antipeptide autoan-
tibodies were associated with alterations in serum FT4 and FT3 levels, as well as in 
the levels of autoantibodies against TPO, Tg and TSH receptor. In Graves’ ophthal-
mopathy, the tissue-specific DIO2 activities were much more reduced and they were 
connected to a lack of appearance of antipeptide autoantibodies. The occurrence 
of anticyspeptide autoantibodies was associated with lower serum FT4 and FT3 
levels compared to those in patients who were negative for these autoantibodies. 
Although, autoantibodies could be demonstrated against eye muscle cytosol anti-
gens, which inhibited the binding of antipeptide antibodies derived from guinea pig 
immunization to eye muscle in immunohistochemical studies, these antieye muscle 
and antipeptide autoantibodies had no pathognomonic role in Graves’ ophthal-
mopathy. These findings above explain why the duality of features causes a greater 
complexity of hyperthyroidism in Graves’ disease.
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